Genetic clue to how patients respond to treatment for Parkinson's Disease

Genetic clue to how patients respond to treatment for Parkinson’s Disease

Researchers have identified a gene variant which explains why some patients with Parkinson's Disease respond well to drug treatment and other do not.

The findings could help to predict treatment responses and tailor therapy to individuals.

Dr Joanne Knight from the Data Science Institute and Faculty of Health and Medicine at Lancaster University was a senior author of the research, featured in Nature Reviews Neurology.

The Rasagiline is used to treat the symptoms of Parkinson's  Disease which include muscle tremors and stiffness.

The response to the drug is typically good in the early stages of the disease but diminishes over time for reasons that are not understood.

The researchers analysed the genetic data from 692 participants of the ADAGIO trial, the largest published trial to look at clinical responses to rasagiline.

With her expertise in handling large datasets, Dr Knight helped identify the two gene variants associated with improved responses to rasagiline in early Parkinson (PD).

She said: "It was exciting to be able to examine data from a clinical trial. Genetic studies of drug response are often based only on memory of the response rather than systematically recorded data. These findings need to be interpreted with caution, as in all studies replication is needed. However, we hope that such studies will encourage other companies to make data from clinical available to researchers."

Explore further

Patients starting Parkinson's drug rasagiline earlier do better

More information: Ian Fyfe. Parkinson disease: Dopamine receptor variants improve response to rasagiline in PD, Nature Reviews Neurology (2016). DOI: 10.1038/nrneurol.2016.83
Journal information: Nature Reviews Neurology

Citation: Genetic clue to how patients respond to treatment for Parkinson's Disease (2016, June 23) retrieved 14 August 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments